New AI Blood Test Could Become Game Changer for Bowel Cancer Diagnosis
By LabMedica International staff writers Posted on 10 Mar 2023 |
Colorectal cancer (CRC), also referred to as bowel cancer, is the world's third most common cancer and the fourth leading cause of death. It is responsible for approximately 1.4 million new cases and 700,000 deaths every year. In Europe, bowel cancer is the second most prevalent cancer, with 450,000 cases annually. Developed countries have seen an increase in incidence of CRC, and the figures remain high. Early detection of CRC has always been crucial in saving lives. Now, the introduction of a fast, affordable, and scalable test for the early detection of bowel cancer could revolutionize the approach to the diagnosis and screening of this disease.
CanSense Ltd. (Swansea, UK) is harnessing artificial intelligence-based modeling (AI) to create a rapid, affordable, and versatile test that can detect bowel cancer in its early stages, save lives and reduce distress. The test could help dramatically reduce the mortality rate of CRC via early stage diagnosis. It also has the potential to reduce the need for unnecessary invasive colonoscopies and the associated financial burden on healthcare providers.
Negative colonoscopy procedures are associated with considerable economic costs, estimated to be a minimum of USD 4.2 billion worldwide. The blood test can serve as a tool to aid healthcare professionals in determining the necessity of further colonoscopy examinations. From the viewpoint of an anxious symptomatic patient, this approach to CRC triage offers significant advantages. The test can yield quick and accurate results, identifying patients requiring immediate and priority treatment. For those given a negative diagnosis, it effectively eliminates the need for colonoscopy procedures and quickly reduces their anxiety.
Related Links:
CanSense Ltd.
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders